Smyth MJ, Young A, Ngiow SF, et al. Targeting adenosine in melanoma. SMR 2017, abstract SMR 02-2.
Omalizumab vermindert jeuk gerelateerd aan checkpointremmers en anti-HER2-therapieën
jun 2021 | Borstkanker, Immuuntherapie, Longoncologie, Uro-oncologie